Gyeonggi-do, South Korea

Dohoon Lee

This inventor holds 1 USPTO granted patent. Top assignee: National Cancer Center. Active years: 2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dohoon Lee. Retrieved from https://idiyas.com/inventor/dohoon-lee-lkfnptz1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Dohoon Lee

Introduction

Dohoon Lee is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biomedical research, particularly in the development of antibodies.

Latest Patents

One of his notable patents is a monoclonal antibody against cotinine and nicotine. This invention aims to neutralize cotinine, a metabolite of nicotine, which has implications for smoking cessation and public health.

Career Highlights

Dohoon Lee is currently affiliated with the National Cancer Center, where he focuses on innovative research that addresses critical health issues. His work is instrumental in advancing the understanding of nicotine's effects on the body.

Collaborations

He collaborates with esteemed colleagues, including Junho Chung and Jae-Gahb Park, to further enhance the impact of their research in the field.

Conclusion

Dohoon Lee's contributions to the development of monoclonal antibodies represent a significant advancement in biomedical research. His work continues to influence the fight against nicotine addiction and improve public health outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…